ArticleScience translational medicine2020
ICOSL
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.Clinical and translational science · 2021Trial
- Article
- Research hotspots and frontiers in the tumor microenvironment of gastric cancer: a bibliometric review from 2005 to 2024.Translational cancer research · 2025Article
- ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche.Nature communications · 2025Article
- Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.Nature communications · 2025Article
- Moniezia benedeni infection promoting ICOSBMC veterinary research · 2025Article
- Mixed Leukocyte Reaction Using Human Plasmacytoid Dendritic Cells and CD4Methods in molecular biology (Clifton, N.J.) · 2025Article
- Network-based analysis and experimental validation of identified natural compounds from Yinchen Wuling San for acute myeloid leukemia.Frontiers in pharmacology · 2025Article
- Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models.Journal for immunotherapy of cancer · 2024Article
- Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.Cell communication and signaling : CCS · 2024Review
- Progress in building clinically relevant patient-derived tumor xenograft models for cancer research.Animal models and experimental medicine · 2023Review
- AutoCore: A network-based definition of the core module of human autoimmunity and autoinflammation.Science advances · 2023Article
- Transplantation elicits a clonally diverse CD8Cell reports · 2023Article
- Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis.Translational vision science & technology · 2023Article
- Humanized mouse models for immuno-oncology research.Nature reviews. Clinical oncology · 2023Review
- Myeloid-derived suppressor cells promote the formation of abdominal aortic aneurysms through the IL-3-ICOSL-ICOS axis.BBA advances · 2023Article
- Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.Arthritis research & therapy · 2022Article
- Milestones in acute GVHD pathophysiology.Frontiers in immunology · 2022Review
- Change in Programmed Death-1 and Inducible Costimulator Expression in Patients whit Acute Myeloid Leukemia Following Chemotherapy and Its Cytogenetic Abnormalities : Change in PD-1 and ICOS Expression in Patients whit AML.Galen medical journal · 2022Article
- Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.The Journal of clinical investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 4 institutions in 1 country.
Djamilatou AdomDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-5225-2205
Stacey R DillonAlpine Immune Sciences, Seattle, WA 98102, USA. paczesns@musc.edu stacey.dillon@alpineimmunesciences.com.ORCID 0000-0001-8758-3795
Jinfeng YangDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Hao LiuDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Abdulraouf RamadanDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Kushi KushekharDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Samantha HundDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-5107-5163
Amanda AlbrightDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Maykala KirkseyDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Titilayo AdeniyanDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Katherine E LewisAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0003-2329-784X
Lawrence EvansAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0003-2744-3867
Rebecca WuAlpine Immune Sciences, Seattle, WA 98102, USA.
Steven D LevinAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0001-9006-1277
Sherri MudriAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0003-1394-0563
Jing YangAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0003-1990-8345
Erika RickelAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0003-2168-6892
Michelle SeabergAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0002-7772-773X
Katherine HendersonAlpine Immune Sciences, Seattle, WA 98102, USA.
Chelsea J GudgeonAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0001-7373-2972
Martin F WolfsonAlpine Immune Sciences, Seattle, WA 98102, USA.
Ryan M SwansonAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0002-5881-1282
Kristine M SwiderekAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0002-4774-0757
Stanford L PengAlpine Immune Sciences, Seattle, WA 98102, USA.ORCID 0000-0001-7445-2542
Keli L HippenDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-8050-270X
Bruce R BlazarDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9608-9841
Sophie PaczesnyDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. paczesns@musc.edu stacey.dillon@alpineimmunesciences.com.ORCID 0000-0001-5571-2775
Alpine Immune Sciences (United States) · USIndiana University School of MedicineUniversity of Minnesota · USMedical University of South Carolina · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MBASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASEST32HL007910 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Roland W. Herzog, Reuben Kapur · 1999 to 2026
$7.6MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MNongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1MTranslating Novel Drug-Targetable Biomarkers to Treat Graft versus Host DiseaseR01CA168814 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PACZESNY, SOPHIE · 2013 to 2024
$3.0MExploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7MDevelopment of first-in-class ST2 inhibitors for treating graft-versus-host diseaseR01HL141432 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PACZESNY, SOPHIE, YANG, CHAO-YIE · 2019 to 2022
$2.6MNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA168814NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL141432NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NHLBI NIH HHS T32 HL007910NIAID NIH HHS R37 AI034495
Abstract
Acute graft-versus-host disease (aGVHD) remains a major complication of allogeneic hematopoietic cell transplantation (HCT). CD146 and CCR5 are proteins that mark activated T helper 17 (Th17) cells. The Th17 cell phenotype is promoted by the interaction of the receptor ICOS on T cells with ICOS ligand (ICOSL) on dendritic cells (DCs). We performed multiparametric flow cytometry in a cohort of 156 HCT recipients and conducted experiments with aGVHD murine models to understand the role of ICOSL
Indexed as
CD28 AntigensGraft vs Host DiseaseAbataceptAnimalsDendritic CellsInducible T-Cell Co-Stimulator ProteinLeukocytes, MononuclearMiceAbataceptCD28 AntigensIcos protein, mouseInducible T-Cell Co-Stimulator Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.